This grant supports the continuation of the Neonatal and Pediatric Pharmacology Research Unit (PPRU) at the Children's Hospital of Michigan and Wayne State University (WSU). The WSU PPRU has conducted more than 40 multicenter and single site trials of drug therapy for pediatric conditions. Studies on aberrant development of serotonin biosynthesis in autistic children using PET scanning and identification of the phenotypic variants of serotonin metabolism have led to the ongoing evaluation of buspirone in drug therapy of autism. Another current area of focus in developing autism treatments involves targeting brain GABA receptors. Support for this research unit will advance rational, safe, effective and cost beneficial drug therapies in the fetus, newborn, and children.